{"transactions":[{"id":4636433,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T21:54:13.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":797,"price":21.17,"value":16872.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."}],"balance_after":23087,"source":{"system":"sec-edgar","filing":"0001919246-26-000131","document":"wk-form4_1791323650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000131/wk-form4_1791323650.xml","form_type":"4"}},{"id":4636432,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T21:53:54.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":558,"price":20.7169,"value":11560.0302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."}],"balance_after":80484,"source":{"system":"sec-edgar","filing":"0001919246-26-000130","document":"wk-form4_1791323632.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000130/wk-form4_1791323632.xml","form_type":"4"}},{"id":4636431,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T21:53:41.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":786,"price":21,"value":16506.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."}],"balance_after":13578,"source":{"system":"sec-edgar","filing":"0001919246-26-000129","document":"wk-form4_1791323618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000129/wk-form4_1791323618.xml","form_type":"4"}},{"id":713370,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":24,"price":27.3254,"value":655.8096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81042,"source":{"system":"sec-edgar","filing":"0001919246-26-000102","document":"wk-form4_1783458235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000102/wk-form4_1783458235.xml","form_type":"4"}},{"id":713369,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":534,"price":26.0303,"value":13900.1802,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81066,"source":{"system":"sec-edgar","filing":"0001919246-26-000102","document":"wk-form4_1783458235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000102/wk-form4_1783458235.xml","form_type":"4"}},{"id":713395,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:38.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":94,"price":27.3604,"value":2571.8776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":14364,"source":{"system":"sec-edgar","filing":"0001919246-26-000101","document":"wk-form4_1783458216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000191924626000101/wk-form4_1783458216.xml","form_type":"4"}},{"id":713394,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:38.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":692,"price":25.9959,"value":17989.1628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":14458,"source":{"system":"sec-edgar","filing":"0001919246-26-000101","document":"wk-form4_1783458216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000191924626000101/wk-form4_1783458216.xml","form_type":"4"}},{"id":713461,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:21.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":85,"price":27.2733,"value":2318.2305,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23884,"source":{"system":"sec-edgar","filing":"0001919246-26-000100","document":"wk-form4_1783458198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000100/wk-form4_1783458198.xml","form_type":"4"}},{"id":713460,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T21:03:21.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":712,"price":25.9954,"value":18508.7248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.58 to $26.53. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23969,"source":{"system":"sec-edgar","filing":"0001919246-26-000100","document":"wk-form4_1783458198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000100/wk-form4_1783458198.xml","form_type":"4"}},{"id":733281,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T21:25:09.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":59,"price":27.9403,"value":1648.4777,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.92 to $28.00. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81600,"source":{"system":"sec-edgar","filing":"0001919246-26-000093","document":"wk-form4_1781731506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000093/wk-form4_1781731506.xml","form_type":"4"}},{"id":733280,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T21:25:09.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":224,"price":27.1245,"value":6075.888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of\nrestricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $26.71 to $27.44. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock\nsold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the issuer full information regarding the number of shares and prices at which the\ntransaction was effected."}],"balance_after":81659,"source":{"system":"sec-edgar","filing":"0001919246-26-000093","document":"wk-form4_1781731506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000093/wk-form4_1781731506.xml","form_type":"4"}},{"id":737534,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:25:26.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":503,"price":28.7261,"value":14449.2283,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":75834,"source":{"system":"sec-edgar","filing":"0001919246-26-000088","document":"wk-form4_1781558723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000088/wk-form4_1781558723.xml","form_type":"4"}},{"id":737533,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T21:25:26.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":35445,"price":27.8046,"value":985534.047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":75331,"source":{"system":"sec-edgar","filing":"0001919246-26-000088","document":"wk-form4_1781558723.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000088/wk-form4_1781558723.xml","form_type":"4"}},{"id":763589,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Stock Option","published_at":"2026-05-26T23:17:24.000Z","date":"2026-05-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents the forfeiture and cancellation of unvested stock options for no consideration pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001919246-26-000081","document":"wk-form4_1779837441.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000191924626000081/wk-form4_1779837441.xml","form_type":"4"}},{"id":763588,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Stock Option","published_at":"2026-05-26T23:17:24.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":59500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.  The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.  The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Represents the acceleration of vesting of stock options pursuant to the Separation Agreement in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer.  The unvested stock options became fully vested and exercisable on May 22, 2026. The transaction is exempt under Rule 16b-3(d). This acceleration does not represent a new grant of options. The stock options may be exercised only until January 15, 2027, subject to the terms of the 2023 Plan and the Separation Agreement."}],"balance_after":59500,"derivative":{"exercise_price":13.5,"exercise_date":"2026-05-22","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":59500},"source":{"system":"sec-edgar","filing":"0001919246-26-000081","document":"wk-form4_1779837441.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000191924626000081/wk-form4_1779837441.xml","form_type":"4"}},{"id":763587,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2026-05-26T23:17:24.000Z","date":"2026-05-22","kind":"sale","planned":false,"acquired":false,"shares":1500,"price":26.8433,"value":40264.95,"ownership":{"direct":false,"nature":"By Lara Knuettel Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an open market sale of the Lara Knuettel Revocable (the \"Trust\") on May 22, 2026.  This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents an open market sale of the Lara Knuettel Revocable (the \"Trust\") on May 22, 2026.  This transaction was executed in multiple trades at prices ranging from $26.66 to $27.16. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC (\"Camden\"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Francis Knuettel II is the co-trustee of the Trust and manager of Camden Capital LLC (\"Camden\"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":11316,"source":{"system":"sec-edgar","filing":"0001919246-26-000081","document":"wk-form4_1779837441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000191924626000081/wk-form4_1779837441.xml","form_type":"4"}},{"id":763586,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2026-05-26T23:17:24.000Z","date":"2026-05-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the forfeiture and cancellation of unvested restricted stock units (\"RSUs\") of  Pelthos Therapeutics Inc. (the \"Issuer\"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the \"Separation Agreement\") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the forfeiture and cancellation of unvested restricted stock units (\"RSUs\") of  Pelthos Therapeutics Inc. (the \"Issuer\"), for no consideration pursuant to that certain Separation Agreement entered into on May 15, 2026 (the \"Separation Agreement\") in connection with the reporting person's termination of employment as Chief Financial Officer of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Separation Agreement provides for the acceleration of vesting of 19,525 RSUs out of the 33,472 previously reported RSUs granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of common stock, par value, $0.0001 per share (\"Common Stock\"), subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The 19,525 unvested RSUs became fully vested on May 22, 2026 upon expiration of the revocation period in the Separation Agreement. The transaction is exempt under Rule 16b-3(d). The acceleration does not represent a new grant of RSUs."}],"balance_after":19525,"source":{"system":"sec-edgar","filing":"0001919246-26-000081","document":"wk-form4_1779837441.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000191924626000081/wk-form4_1779837441.xml","form_type":"4"}},{"id":774294,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:11:12.000Z","date":"2026-05-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":144,"price":27.007,"value":3889.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.00 to $27.0101. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":81883,"source":{"system":"sec-edgar","filing":"0001919246-26-000073","document":"wk-form4_1779142269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000073/wk-form4_1779142269.xml","form_type":"4"}},{"id":814126,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:21.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":280,"price":21.3612,"value":5981.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27422,"source":{"system":"sec-edgar","filing":"0001919246-26-000055","document":"wk-form4_1775509399.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000191924626000055/wk-form4_1775509399.xml","form_type":"4"}},{"id":814125,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:21.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":310,"price":20.5126,"value":6358.906,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27702,"source":{"system":"sec-edgar","filing":"0001919246-26-000055","document":"wk-form4_1775509399.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000191924626000055/wk-form4_1775509399.xml","form_type":"4"}},{"id":814156,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:04.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":265,"price":21.3612,"value":5660.718,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":82027,"source":{"system":"sec-edgar","filing":"0001919246-26-000054","document":"wk-form4_1775509382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000054/wk-form4_1775509382.xml","form_type":"4"}},{"id":814155,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:03:04.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":293,"price":20.5121,"value":6010.0453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":82292,"source":{"system":"sec-edgar","filing":"0001919246-26-000054","document":"wk-form4_1775509382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000054/wk-form4_1775509382.xml","form_type":"4"}},{"id":814227,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:02:43.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":371,"price":21.3628,"value":7925.5988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":15150,"source":{"system":"sec-edgar","filing":"0001919246-26-000053","document":"wk-form4_1775509361.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000191924626000053/wk-form4_1775509361.xml","form_type":"4"}},{"id":814226,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:02:43.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":415,"price":20.5154,"value":8513.891,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":15521,"source":{"system":"sec-edgar","filing":"0001919246-26-000053","document":"wk-form4_1775509361.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000191924626000053/wk-form4_1775509361.xml","form_type":"4"}},{"id":814318,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:01:00.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":377,"price":21.3614,"value":8053.2478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":24681,"source":{"system":"sec-edgar","filing":"0001919246-26-000052","document":"wk-form4_1775509257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000052/wk-form4_1775509257.xml","form_type":"4"}},{"id":814317,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-06T21:01:00.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":420,"price":20.5151,"value":8616.342,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":25058,"source":{"system":"sec-edgar","filing":"0001919246-26-000052","document":"wk-form4_1775509257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000052/wk-form4_1775509257.xml","form_type":"4"}},{"id":822492,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":82585,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822491,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":63477,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822490,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:39.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":6450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":61023,"source":{"system":"sec-edgar","filing":"0001919246-26-000047","document":"wk-form4a_1775079936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000191924626000047/wk-form4a_1775079936.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822610,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":39886,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822609,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":4961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":20778,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822608,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:45:20.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":12900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":15817,"source":{"system":"sec-edgar","filing":"0001919246-26-000046","document":"wk-form4a_1775079918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000191924626000046/wk-form4a_1775079918.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822400,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:44:43.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":28012,"source":{"system":"sec-edgar","filing":"0001919246-26-000045","document":"wk-form4a_1775079878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000191924626000045/wk-form4a_1775079878.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822399,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:44:43.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":2454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":8904,"source":{"system":"sec-edgar","filing":"0001919246-26-000045","document":"wk-form4a_1775079878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000191924626000045/wk-form4a_1775079878.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822398,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:44:43.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":6450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"From June 18, 2024 to July 7, 2025, the reporting person  filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the \"Original Form 4s\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":6450,"source":{"system":"sec-edgar","filing":"0001919246-26-000045","document":"wk-form4a_1775079878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000191924626000045/wk-form4a_1775079878.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822636,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:43:41.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":25478,"source":{"system":"sec-edgar","filing":"0001919246-26-000043","document":"wk-form4a_1775079819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000191924626000043/wk-form4a_1775079819.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822541,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:42:47.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":25478,"source":{"system":"sec-edgar","filing":"0001919246-26-000042","document":"wk-form4a_1775079764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000191924626000042/wk-form4a_1775079764.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822355,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54561,"kind":"person","name":"Baxter Richard B","position":1,"cik":"0002075922","reported_name":"Baxter Richard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-01T21:42:03.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":19108,"source":{"system":"sec-edgar","filing":"0001919246-26-000040","document":"wk-form4a_1775079720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000040/wk-form4a_1775079720.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822767,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2026-04-01T21:39:34.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":33472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":33472,"source":{"system":"sec-edgar","filing":"0001919246-26-000039","document":"wk-form4a_1775079571.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000191924626000039/wk-form4a_1775079571.xml","form_type":"4/A","original_submission_date":"2025-07-07"}},{"id":822472,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54589,"kind":"person","name":"Plesha Scott M.","position":1,"cik":"0001726687","reported_name":"Plesha Scott M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-04-01T17:44:11.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":83678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":83678,"source":{"system":"sec-edgar","filing":"0001919246-26-000044","document":"wk-form4a_1775079846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726687/000191924626000044/wk-form4a_1775079846.xml","form_type":"4/A","original_submission_date":"2025-07-23"}},{"id":823222,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54760,"kind":"person","name":"Rangarao Sai","position":1,"cik":"0002077227","reported_name":"Rangarao Sai","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-04-01T17:42:25.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":30518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock, par value $0.0001 per share (\"Common Stock\") of Pelthos Therapeutics Inc. (the \"Issuer\"), issuable upon settlement of restricted stock units of the Issuer (\"RSUs\") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the \"2023 Plan\"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the \"Original Form 4\").  This Form 4 amendment (this \"Amendment\") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary."}],"balance_after":30518,"source":{"system":"sec-edgar","filing":"0001919246-26-000041","document":"wk-form4a_1775079742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077227/000191924626000041/wk-form4a_1775079742.xml","form_type":"4/A","original_submission_date":"2025-07-21"}},{"id":957935,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":70813,"kind":"person","name":"Einhorn Andrew J.","position":1,"cik":"0001560685","reported_name":"Einhorn Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-29T16:16:56.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the \"RSUs\") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the \"Plan\"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the \"RSUs\") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the \"Plan\"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001753926-25-001991","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560685/000175392625001991/ownership.xml","form_type":"4"}},{"id":962570,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2025-12-19T21:15:06.000Z","date":"2025-12-17","kind":"grant","planned":false,"acquired":true,"reported_value":9000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."}],"derivative":{"exercise_price":29.73,"exercise_date":"2025-11-06","expiration_date":"2027-11-06","underlying":"Common Stock","underlying_shares":302724},"source":{"system":"sec-edgar","filing":"0001193125-25-326891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000119312525326891/ownership.xml","form_type":"4"}},{"id":962569,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2025-12-19T21:15:06.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"reported_value":9000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Convertible Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 17, 2025, at the annual meeting of the Issuer's shareholders, the Issuer's shareholders approved the waiver of the limit on the number of shares of Common Stock that may be issued to the holders of the Convertible Notes pursuant to the rules of the NYSE American LLC, which requires shareholder approval before issuing common stock (or securities convertible into or exercisable for common stock) in a private placement that constitutes 20% or more of the Issuer's pre-transaction outstanding common stock.  As a result, the conversion price of the Convertible Note was reduced from $34.442 per share to $29.73 per share.  The reduction in the conversion price is reported above as the cancellation of a Convertible Note and the acquisition of a new Convertible Note."}],"balance_after":0,"derivative":{"exercise_price":34.442,"exercise_date":"2025-11-06","expiration_date":"2027-11-06","underlying":"Common Stock","underlying_shares":261309},"source":{"system":"sec-edgar","filing":"0001193125-25-326891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000119312525326891/ownership.xml","form_type":"4"}},{"id":970749,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-12-12T22:01:02.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":2123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of issuer's Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":14862,"derivative":{"underlying":"Common Stock","underlying_shares":2123},"source":{"system":"sec-edgar","filing":"0001753926-25-001884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001884/ownership.xml","form_type":"4"}},{"id":970748,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-12-12T22:01:02.000Z","date":"2025-07-02","kind":"exercise","planned":false,"acquired":false,"shares":8493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of issuer's Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":16985,"derivative":{"underlying":"Common Stock","underlying_shares":8493},"source":{"system":"sec-edgar","filing":"0001753926-25-001884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001884/ownership.xml","form_type":"4"}},{"id":970747,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:01:02.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":false,"shares":9542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On December 10, 2025, the Reporting Person transferred 9,542 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The Reporting Person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the Reporting Person disclaims beneficial ownership of the shares held by the Trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any."}],"balance_after":1074,"source":{"system":"sec-edgar","filing":"0001753926-25-001884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001884/ownership.xml","form_type":"4"}},{"id":970746,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:01:02.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":2123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":10616,"source":{"system":"sec-edgar","filing":"0001753926-25-001884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001884/ownership.xml","form_type":"4"}},{"id":970745,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-12T22:01:02.000Z","date":"2025-07-02","kind":"exercise","planned":false,"acquired":true,"shares":8493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units (\"RSUs\"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":8493,"source":{"system":"sec-edgar","filing":"0001753926-25-001884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001884/ownership.xml","form_type":"4"}},{"id":986573,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":28.005,"value":56010.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986572,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":1,"price":28.5,"value":28.5,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986571,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":28.135,"value":56270.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":32001,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":986570,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T17:37:02.000Z","date":"2025-11-25","kind":"sale","planned":false,"acquired":false,"shares":5999,"price":28,"value":167972.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":34001,"source":{"system":"sec-edgar","filing":"0001753926-25-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001831/ownership.xml","form_type":"4"}},{"id":1004279,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Senior Secured Convertible Note","published_at":"2025-11-10T21:43:18.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"price":9000000,"reported_value":9000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F1","text":"On November 6, 2025, Pelthos Therapeutics Inc. (the \"Issuer\") entered into a Securities Purchase Agreement with the reporting person and certain other investors, pursuant to which the Issuer issued a senior secured convertible note (the \"Convertible Note\") in the aggregate principal amount of $9 million to the reporting person on November 6, 2025. The Convertible Note may be converted into Common Stock at a conversion price of $34.442 per share. The Note includes a beneficial ownership limitation of 49.9% with respect to the reporting person."}],"derivative":{"exercise_price":34.442,"underlying":"Common Stock","underlying_shares":261309},"source":{"system":"sec-edgar","filing":"0001193125-25-274436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000119312525274436/ownership.xml","form_type":"4"}},{"id":1082637,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54589,"kind":"person","name":"Plesha Scott M.","position":1,"cik":"0001726687","reported_name":"Plesha Scott M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option","published_at":"2025-07-23T21:17:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":255000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":255000,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001753926-25-001175","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726687/000175392625001175/ownership.xml","form_type":"4"}},{"id":1082636,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54589,"kind":"person","name":"Plesha Scott M.","position":1,"cik":"0001726687","reported_name":"Plesha Scott M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-07-23T21:17:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":83678,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":83678,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":83678},"source":{"system":"sec-edgar","filing":"0001753926-25-001175","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726687/000175392625001175/ownership.xml","form_type":"4"}},{"id":1084187,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54760,"kind":"person","name":"Rangarao Sai","position":1,"cik":"0002077227","reported_name":"Rangarao Sai","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2025-07-21T20:26:43.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":93000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 93,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 93,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":93000,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001753926-25-001158","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2077227/000175392625001158/ownership.xml","form_type":"4"}},{"id":1084186,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54760,"kind":"person","name":"Rangarao Sai","position":1,"cik":"0002077227","reported_name":"Rangarao Sai","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-21T20:26:43.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":30518,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 30,518 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 30,518 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":30518,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":30518},"source":{"system":"sec-edgar","filing":"0001753926-25-001158","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077227/000175392625001158/ownership.xml","form_type":"4"}},{"id":1091036,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54561,"kind":"person","name":"Baxter Richard B","position":1,"cik":"0002075922","reported_name":"Baxter Richard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:47:34.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001109/ownership.xml","form_type":"4"}},{"id":1091035,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":54561,"kind":"person","name":"Baxter Richard B","position":1,"cik":"0002075922","reported_name":"Baxter Richard B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:47:34.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."}],"balance_after":19108,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001109/ownership.xml","form_type":"4"}},{"id":1091174,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:46:35.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":77640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":77640,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":77640},"source":{"system":"sec-edgar","filing":"0001753926-25-001108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000175392625001108/ownership.xml","form_type":"4"}},{"id":1091173,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31647,"kind":"person","name":"Greenleaf Peter","position":1,"cik":"0001363683","reported_name":"Greenleaf Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:46:35.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":25478,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":25478},"source":{"system":"sec-edgar","filing":"0001753926-25-001108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363683/000175392625001108/ownership.xml","form_type":"4"}},{"id":1091089,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:45:34.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":77640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":77640,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":77640},"source":{"system":"sec-edgar","filing":"0001753926-25-001107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001107/ownership.xml","form_type":"4"}},{"id":1091088,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31635,"kind":"person","name":"Pauls Matthew","position":1,"cik":"0001573429","reported_name":"Pauls Matthew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:45:34.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":25478,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":25478,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":25478},"source":{"system":"sec-edgar","filing":"0001753926-25-001107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1573429/000175392625001107/ownership.xml","form_type":"4"}},{"id":1091222,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Stock Option","published_at":"2025-07-08T01:44:42.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":102000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":145074,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":102000},"source":{"system":"sec-edgar","filing":"0001753926-25-001106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625001106/ownership.xml","form_type":"4"}},{"id":1091221,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, Treas & Secty"}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:44:42.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":33472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years."}],"balance_after":33472,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":33472},"source":{"system":"sec-edgar","filing":"0001753926-25-001106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625001106/ownership.xml","form_type":"4"}},{"id":1091164,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:43:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001105/ownership.xml","form_type":"4"}},{"id":1091163,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:43:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":36969,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001105/ownership.xml","form_type":"4"}},{"id":1091067,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:42:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001104/ownership.xml","form_type":"4"}},{"id":1091066,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:42:40.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted stock restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":28012,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001104/ownership.xml","form_type":"4"}},{"id":1091050,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-07-08T01:41:33.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":58230,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."}],"balance_after":58230,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":58230},"source":{"system":"sec-edgar","filing":"0001753926-25-001103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000175392625001103/ownership.xml","form_type":"4"}},{"id":1091049,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-07-08T01:41:33.000Z","date":"2025-07-02","kind":"grant","planned":false,"acquired":true,"shares":19108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":28012,"derivative":{"exercise_price":13.5,"exercise_date":"2026-07-02","expiration_date":"2035-07-02","underlying":"Common Stock","underlying_shares":19108},"source":{"system":"sec-edgar","filing":"0001753926-25-001103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000175392625001103/ownership.xml","form_type":"4"}},{"id":1091804,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091803,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091802,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091801,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":92072},"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091800,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":10,"value":400000.0,"ownership":{"direct":false,"nature":"By Key Recovery Group LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1091799,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:05:54.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":10,"value":400000.0,"ownership":{"direct":false,"nature":"By Balmoral Financial Group LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Ezra Friedberg is the manager of Balmoral Financial Group LLC (\"Balmoral\") and the manager of Key Recovery Group LLC (\"Key\"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001753926-25-001079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392625001079/ownership.xml","form_type":"4"}},{"id":1092227,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:04:18.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Francis Knuettel II is the manager of Camden Capital LLC (\"Camden\") and the co-trustee of the Lara Knuettel Revocable Trust (the \"Trust\"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001753926-25-001077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625001077/ownership.xml","form_type":"4"}},{"id":1092226,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:04:18.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Acquired in connection with cancellation of promissory note."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Francis Knuettel II is the manager of Camden Capital LLC (\"Camden\") and the co-trustee of the Lara Knuettel Revocable Trust (the \"Trust\"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":10000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001753926-25-001077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625001077/ownership.xml","form_type":"4"}},{"id":1092225,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-04T01:04:18.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":10,"value":100000.0,"ownership":{"direct":false,"nature":"By Camden Capital LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Francis Knuettel II is the manager of Camden Capital LLC (\"Camden\") and the co-trustee of the Lara Knuettel Revocable Trust (the \"Trust\"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001753926-25-001077","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625001077/ownership.xml","form_type":"4"}},{"id":1091915,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":true,"shares":31278.681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"shares","element":"transactionShares","label":"F4","text":"Received in exchange for shares of LNHC, Inc. (\"LNHC\") common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for shares of LNHC, Inc. (\"LNHC\") common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":3127868,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":3127868},"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1091914,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":3000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1091913,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-04T01:02:33.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":1500000,"price":10,"value":15000000.0,"ownership":{"direct":false,"nature":"By Ligand Pharmaceuticals Incorporated"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. (\"Ligand\"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0001753926-25-001075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392625001075/ownership.xml","form_type":"4"}},{"id":1093523,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-03T13:33:45.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":true,"shares":31278.681,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."}],"balance_after":34278.681,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":3127868},"source":{"system":"sec-edgar","filing":"0000950170-25-093589","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000095017025093589/ownership.xml","form_type":"4"}},{"id":1093522,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-07-03T13:33:45.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.  The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion."}],"balance_after":3000,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0000950170-25-093589","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000095017025093589/ownership.xml","form_type":"4"}},{"id":1093521,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND","position":1,"cik":"0000886163","reported_name":"LIGAND PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-03T13:33:45.000Z","date":"2025-07-01","kind":"exercise","planned":false,"acquired":true,"shares":1500000,"price":10,"value":15000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The numbers  reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025."}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0000950170-25-093589","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000095017025093589/ownership.xml","form_type":"4"}},{"id":1171551,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":73556,"kind":"person","name":"Simmons Chia-Lin","position":1,"cik":"0001868194","reported_name":"Simmons Chia-Lin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-04-16T01:31:27.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"date","element":"transactionDate","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"shares","element":"transactionShares","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."}],"balance_after":130000,"derivative":{"exercise_price":1.35,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001753926-25-000644","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1868194/000175392625000644/ownership.xml","form_type":"4"}},{"id":1171747,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO, Treas & Secty"}}],"security":"Stock Option","published_at":"2025-04-16T01:30:47.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":53988,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"date","element":"transactionDate","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"shares","element":"transactionShares","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction."}],"balance_after":430736,"derivative":{"exercise_price":1.35,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":53988},"source":{"system":"sec-edgar","filing":"0001753926-25-000643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392625000643/ownership.xml","form_type":"4"}},{"id":1363375,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-15T21:22:20.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":49605,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."}],"balance_after":263306,"derivative":{"exercise_price":0.64,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":49605},"source":{"system":"sec-edgar","filing":"0001753926-24-001951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1392029/000175392624001951/ownership.xml","form_type":"4"}},{"id":1363117,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-15T21:20:59.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":24533,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."}],"balance_after":116098,"derivative":{"exercise_price":0.64,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":24533},"source":{"system":"sec-edgar","filing":"0001753926-24-001949","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000175392624001949/ownership.xml","form_type":"4"}},{"id":1363124,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":31625,"kind":"person","name":"Friedberg Ezra M","position":1,"cik":"0001679440","reported_name":"Friedberg Ezra M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-15T21:19:00.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":24533,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters."}],"balance_after":634752,"derivative":{"exercise_price":0.64,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":24533},"source":{"system":"sec-edgar","filing":"0001753926-24-001947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679440/000175392624001947/ownership.xml","form_type":"4"}},{"id":1406313,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":53559,"kind":"person","name":"Malamut Richard","position":1,"cik":"0001772168","reported_name":"Malamut Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:56:55.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":10400,"price":0.9447,"value":9824.88,"ownership":{"direct":false,"nature":"Jointly held with spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average price of the shares purchased ranging from $0.9206 to $0.9554 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":91565,"source":{"system":"sec-edgar","filing":"0001753926-24-001578","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1772168/000175392624001578/ownership.xml","form_type":"4"}},{"id":1406572,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2024-09-16T20:55:23.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":3500,"price":0.97,"value":3395.0,"ownership":{"direct":false,"nature":"By Lara Knuettel Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.94 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":547710,"source":{"system":"sec-edgar","filing":"0001753926-24-001576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001576/ownership.xml","form_type":"4"}},{"id":1406571,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2024-09-16T20:55:23.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":1700,"price":0.97,"value":1649.0,"ownership":{"direct":false,"nature":"By Lara Knuettel Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.93 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":544210,"source":{"system":"sec-edgar","filing":"0001753926-24-001576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001576/ownership.xml","form_type":"4"}},{"id":1408538,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2024-09-12T21:35:41.000Z","date":"2024-09-11","kind":"purchase","planned":false,"acquired":true,"shares":5500,"price":0.94,"value":5170.0,"ownership":{"direct":false,"nature":"By Lara Knuettel Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.89 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":542510,"source":{"system":"sec-edgar","filing":"0001753926-24-001570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001570/ownership.xml","form_type":"4"}},{"id":1408537,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO, Treas & Secty"}}],"security":"Common Stock","published_at":"2024-09-12T21:35:41.000Z","date":"2024-09-10","kind":"purchase","planned":false,"acquired":true,"shares":6500,"price":0.89,"value":5785.0,"ownership":{"direct":false,"nature":"By Lara Knuettel Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.80 to $0.92 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4."}],"balance_after":537010,"source":{"system":"sec-edgar","filing":"0001753926-24-001570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001570/ownership.xml","form_type":"4"}},{"id":1462786,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO Treas & Secty"}}],"security":"Common Stock","published_at":"2024-07-02T21:17:42.000Z","date":"2024-06-28","kind":"gift","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":515510,"source":{"system":"sec-edgar","filing":"0001753926-24-001211","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001211/ownership.xml","form_type":"4"}},{"id":1462785,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO Treas & Secty"}}],"security":"Common Stock","published_at":"2024-07-02T21:17:42.000Z","date":"2024-06-28","kind":"gift","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":530510,"source":{"system":"sec-edgar","filing":"0001753926-24-001211","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001211/ownership.xml","form_type":"4"}},{"id":1475082,"issuer":{"id":6798,"kind":"organization","name":"Pelthos Therapeutics Inc.","symbol":"PTHS"},"owners":[{"id":39641,"kind":"person","name":"Francis Knuettel II","position":1,"cik":"0001433316","reported_name":"Francis Knuettel II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Pres., CFO Treas & Secty"}}],"security":"Employee Stock Option","published_at":"2024-06-19T00:07:21.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":2778,"ownership":{"direct":false,"nature":"Camden Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities."}],"balance_after":25001,"derivative":{"exercise_price":22.68,"exercise_date":"2024-02-21","expiration_date":"2033-01-10","underlying":"Common Stock","underlying_shares":2778},"source":{"system":"sec-edgar","filing":"0001753926-24-001139","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1433316/000175392624001139/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-21"}}],"next_cursor":"2024-06-19T00:07:21.000000Z,1475082"}